Oncogenic cancer/testis antigens: prime candidates for immunotherapy
Morten F Gjerstorff1, Mads H Andersen2, Henrik J Ditzel1,3
1Department of Cancer and Inflammation Research, University of Southern Denmark, Odense, Denmark.
Abstract:
Recent developments have set the stage for immunotherapy as a supplement to conventional cancer treatment. Consequently, a significant effort is required to further improve efficacy and specificity, particularly the identification of optimal therapeutic targets for clinical testing. Cancer/testis antigens are immunogenic, highly cancer-specific, and frequently expressed in various types of cancer, which make them promising candidate targets for cancer immunotherapy, including cancer vaccination and adoptive T-cell transfer with chimeric T-cell receptors. Our current understanding of tumor immunology and immune escape suggests that targeting oncogenic antigens may be beneficial, meaning that identification of cancer/testis antigens with oncogenic properties is of high priority. Recent work from our lab and others provide evidence that many cancer/testis antigens, in fact, have oncogenic functions, including support of growth, survival and metastasis. This novel insight into the function of cancer/testis antigens has the potential to deliver more effective cancer vaccines. Moreover, immune targeting of oncogenic cancer/testis antigens in combination with conventional cytotoxic therapies or novel immunotherapies such as checkpoint blockade or adoptive transfer, represents a highly synergistic approach with the potential to improve patient survival.
Insights
Cancer/testis antigens show promise as immunotherapy targets due to their cancer-specific expression and oncogenic functions. Targeting these antigens may lead to more effective cancer vaccines and improved patient survival.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Immunotherapy is emerging as a key adjunct to traditional cancer treatments.
- Improving the efficacy and specificity of cancer immunotherapies requires identifying optimal therapeutic targets.
- Cancer/testis antigens are highly specific to tumors and immunogenic, making them attractive targets.
Purpose of the Study:
- To highlight the potential of cancer/testis antigens as targets for novel cancer immunotherapies.
- To emphasize the oncogenic functions of cancer/testis antigens and their implications for treatment strategies.
- To underscore the synergistic potential of targeting these antigens with existing and emerging therapies.
Main Methods:
- Review of recent research on cancer/testis antigens and tumor immunology.
- Analysis of evidence supporting the oncogenic functions of cancer/testis antigens.
- Exploration of therapeutic strategies involving cancer/testis antigens.
Main Results:
- Many cancer/testis antigens possess oncogenic properties, supporting tumor growth, survival, and metastasis.
- These antigens are suitable targets for cancer vaccination and adoptive T-cell transfer.
- Targeting oncogenic cancer/testis antigens offers a synergistic approach when combined with other cancer therapies.
Conclusions:
- Cancer/testis antigens with oncogenic functions represent a high-priority target class for cancer immunotherapy.
- Leveraging the oncogenic roles of these antigens can enhance the development of more effective cancer vaccines.
- Combination therapies involving oncogenic cancer/testis antigens hold significant promise for improving patient outcomes.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:18Cancer
02:56Treatment Resistent Cancers